Indications
Xigris is indicated for the treatment of adult patients with severe sepsis with multiple organ failure when added to best standard care. The use of Xigris should be considered mainly in situations when therapy can be started within 24 hours after the onset of organ failure (for further information see section 5.1).
Composition
- Active substance
- drotrecogin alfa (activated)
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Xigris
- Active substance
- drotrecogin alfa (activated)
- ATC code
- B01AD10
- Therapeutic area
- Sepsis, Multiple Organ Failure
- Marketing authorisation holder